ClinicalTrials.gg
CompletedNCT06118866Updated Jun 4, 2025

A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia

A Phase 2 interventional study of placebo-Q2W and HMI-115-120mg-Q4W in Androgenetic Alopecia, sponsored by Hope Medicine (Nanjing) Co., Ltd. Completed at 1 site in China. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-06-04.

Sponsored by Hope Medicine (Nanjing) Co., Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Alopecia with a site in China — 12 open to participants now, 14 under way, 4 of them phase 3. Alopecia · China.

Enrollment
10th of 32
192 · median 128
Started
2023
with 4 others
Phase 2
9 of 33
2 open now
Registered
7th of 33
by date

Among the 33 studies in Alopecia with a site in China, this one is the 10th largest by enrollment of the 32 interventional ones that give a count, is one of 5 that started in 2023, is one of 9 in phase 2, and was the 7th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

12 of the 33 studies in Alopecia with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 65 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Alopecia with a site in China, or all of them as a file.
02

Study summary

To investigate the efficacy of HMI-115 compared to placebo in treating Androgenic Alopecia patients for 24 weeks

03

Conditions studied

  • Androgenetic Alopecia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must have given written before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects.
  2. Male subjects, between 18 and 65 years of age, inclusive, at the time of signing informed consent.
  3. Clinical diagnosis of androgenetic alopecia. Male subjects who meet Norwood-Hamilton scales III vertex, IV and V .
  4. Be willing and able to comply with all study assessments and adhere to the protocol schedule and restrictions, including having a small circle about 1 cm2 of hair clipped to approximate 1 mm in length and micro-dot-tattoo on the scalp of target area.
  5. Subjects who are willing to keep the same hair color, refrain from hair weaving, and hair growth therapy and supplement (except for protocol specified IMP) during the study.
  6. Subjects agree to use required methods from signing the consent until 3 months after the last dose of IMP or complete whole study period whichever is longer.

Exclusion criteria

Exclusion Criteria:

  1. Subject with history of scalp radiation or surgery which could interfere study assessment (e.g., hair transplantation surgery).
  2. Subject with history of scalp laser treatment within 6 months prior screening, including but not limited to, low level laser, and fractional laser, etc.
  3. Subject with history of hair weaves within 3 months prior screening.
  4. Subject has a current history of hyperthyroidism or uncontrolled hypothyroidism.
  5. Subject has, in the Investigator's opinion, uncontrolled hypertension (systolic blood pressure [SBP] > 159 mmHg, diastolic blood pressure [DBP] > 99 mmHg).
  6. Subject has any of the following conditions within 6 weeks prior to Screening:

    1. Myocardial infarction, stroke, unstable angina, or .
    2. Heart failure with classified as being in Class III or IV.
  7. Subject has high fever, major surgery, or ten percent or more weight decrease within three months before screening.
  8. Subject with history of active (with or without systemic chemotherapy), except treated basal cell carcinoma of the skin (besides scalp).
  9. Subject plans to schedule elective surgery during the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
192 participants (actual)

Study arms

  • Placebo comparator
    placebo-Q2W

    placebo, 0mg/vials

    Drug: placebo-Q2W

  • Active comparator
    HMI-115-120mg-Q4W

    HMI-115, 60mg/vials

    Drug: HMI-115-120mg-Q4W

  • Active comparator
    HMI-115-240mg-Q4W

    HMI-115, 60mg/vials

    Drug: HMI-115-240mg-Q4W

  • Active comparator
    HMI-115-240mg-Q2W

    HMI-115, 60mg/vials

    Drug: HMI-115, 240mg-Q2W

Interventions

  • Drugplacebo-Q2W

    placebo, 0mg,SC,Q2W,12 cycles

  • HMI-115, 120mg,SC,Q4W,6 cycles(Placebo given in the second week of each cycle)

  • HMI-115, 240mg,SC,Q4W,6 cycles(Placebo given in the second week of each cycle)

  • HMI-115, 240mg,SC,Q2W,12 cycles

06

What researchers measure

Primary outcomes

  1. The Rate of Target Arean Hair Count (TAHC)

    The mean change in TAHC of non-vellus from baseline

    Time frame: 24 Weeks

Secondary outcomes

  1. Hair Growth State Assessed by Hair Growth Questionnaire Assessment (HGQA)

    To assess the hair growth by 7-question questionnaire and summary the number and percentage of subjects in each category for each HGQA question.

    Time frame: 6 weeks, 12 weeks, 18 weeks, 24 weeks, and 36 weeks

  2. Target Area Hair Count (TAHC) change from baseline

    The mean change in TAHC of non-vellus from Baseline

    Time frame: 6 weeks, 12 weeks, 18 weeks, 24 weeks, and 36 weeks

  3. Rate of Target Area Hair Width (TAHW)

    The mean change in TAHW of non-vellus from baseline

    Time frame: 6 weeks, 12 weeks, 18 weeks, 24 weeks, and 36 weeks

  4. Investigator Global Assessment (IGA)

    Summary of subject number and percentage in each IGA category

    Time frame: 6 weeks, 12 weeks, 18 weeks, 24 weeks, and 36 weeks

  5. Subject Self-Assessment (SSA)

    Summary of subject number and percentage in each SSA category

    Time frame: 6 weeks, 12 weeks, 18 weeks, 24 weeks, and 36 weeks

  6. Norwood-Hamilton Grade change from baseline

    Summary of subject number and percentage in each grade of Norwood-Hamilton Scale

    Time frame: 12 weeks, 24 weeks, and 36 weeks

  7. Frequencies and percentages of Adverse event (AE)

    Frequency and percentages of subjects with treatment-emergent AE (TEAE) will be calculated and TEAE will be summarized by systematic organ classification (SOC), preferred term (PT), relationship to study treatment, maximum severity, whether resulting in death, whether resulting in study treatment discontinuation, belong to serious AE (SAE) or not, belong to events of special interest (AESI) or not.

    Time frame: 36Weeks

  8. Blood Pressure change from baseline

    Descriptive statistics summarizing changes in blood pressure (systolic and diastolic) will be compared between baseline levels and each predetermined time point.

    Time frame: 36 Weeks

  9. Pulse change from baseline

    Descriptive statistics summarizing changes in pulse will be compared between baseline levels and each predetermined time point.

    Time frame: 36 Weeks

  10. Body temperature change from baseline

    Descriptive statistics summarizing changes in body temperature will be compared between baseline levels and each predetermined time point.

    Time frame: 36 Weeks

  11. Respiratory rate

    Descriptive statistics summarizing changes in respiratory rate will be compared between baseline levels and each predetermined time point.

    Time frame: 36 Weeks

  12. Complete or brief physical examination, at a minimum of General appearance, HEENT (head, eyes, ears, nose, throat), Neck, Lung/pulmonary, Chest, Neurological or not, Extremities,ect.to assess the physical health state.

    Physical examination findings by body system will be summarized, presented with frequency counts and percentages. A complete or brief physical examination will be performed at Visit 1, Visit 2, End of Treatment Visit and Follow-up Visit. Height (cm) and weight (kg) will be measured and body mass index will be calculated and recorded at specified period.

    Time frame: 36 Weeks

  13. Concomitant Medication

    Concomitant medication usage will be summarized by the number and proportion of subjects and classified by the World Health Organization Drug Dictionary (WHO DD) based on Anatomical Therapeutic Chemical Classification System (ATC) code level 3.

    Time frame: 36 Weeks

  14. Change in twelve-lead electrocardiogram parameters

    Change in electrocardiogram parameters including heart rate (HR), QRS, RR, PR, and QT interval (QTcF and QTcB) relative to baseline will be summarized descriptively by visits and groups. The within-group changes from baseline to each visit will be summarized and will be compared with a paired t-test for continuous measurements. Subject number and percentage with other clinically significant electrocardiogram findings in each visit will be summarized by groups. A general assessment of the 12-lead electrocardiogram will be presented as normal, abnormal clinical significance, or abnormal no clinical significance.

    Time frame: 36 Weeks

  15. Clinical laboratory tests of hematology

    Descriptive statistics summarizing changes in results of clinical laboratory tests of hematology from baseline levels at each predetermined time point. Shift tables for changes from baseline according to the normal minimum and maximum will be provided.

    Time frame: 36 Weeks

  16. Clinical laboratory tests of coagulation

    Descriptive statistics summarizing changes in results of clinical laboratory tests of coagulation from baseline levels at each predetermined time point. Shift tables for changes from baseline according to the normal minimum and maximum will be provided.

    Time frame: 36 Weeks

  17. Clinical laboratory tests of clinical chemistry

    Descriptive statistics summarizing changes in results of clinical laboratory tests of clinical chemistry from baseline levels at each predetermined time point. Shift tables for changes from baseline according to the normal minimum and maximum will be provided.

    Time frame: 36 Weeks

  18. Clinical laboratory tests of urinalysis

    Descriptive statistics summarizing changes in results of clinical laboratory tests of urinalysis from baseline levels at each predetermined time point. Shift tables for changes from baseline according to the normal minimum and maximum will be provided.

    Time frame: 36 Weeks

  19. Clinical laboratory tests of hormones

    Descriptive statistics summarizing changes in results of clinical laboratory tests of hormones from baseline levels at each predetermined time point. Shift tables for changes from baseline according to the normal minimum and maximum will be provided.

    Time frame: 36 Weeks

07

Study locations

1 site
  • Peking University People's Hospital
    Beijing, Beijing 100035, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2023 to primary completion in Aug 2024, 11 months.

Of 25 industry-sponsored phase 2 interventional studies under Alopecia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's 11 months is close to that.

Counting every sponsor, half of 42 studies reached it within 13 months; a quarter within 9 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2023
First posted
Nov 7, 2023
StartActual
Sep 11, 2023
Primary completionActual
Aug 26, 2024
CompletionActual
Nov 28, 2024
Last update
Jun 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06118866
Lead sponsor
Hope Medicine (Nanjing) Co., Ltd
Responsible party
Sponsor
First posted
Nov 7, 2023
Start date
Sep 11, 2023
Primary completion
Aug 26, 2024
Completion
Nov 28, 2024
Last update
Jun 4, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HMI-115

Start the discussion